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A better education and training of clinical investigators and their teams is one of
the factors that could foster the development of clinical research in Europe, a key
objective of the Innovative Medicines Initiative (IMI). PharmaTrain (an IMI programme
on training in medicines development), and European Clinical Research Infrastructures
Network (ECRIN) have joined forces to address this issue. An advisory group composed
of representatives of universities, pharmaceutical companies and other organisations
met four times between June 2011 and July 2012. This resulted in a position paper
proposing a strategy to improve and harmonize clinical investigator training in Europe,
and including a detailed syllabus and list of learning outcomes. Major recommendations
are the establishment of minimal and mutually recognized certification requirement for
investigators throughout the EU and the creation of a European platform to provide a
suitable course and examination infrastructure.
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THE NEED FOR IMPROVED AND HARMONISED
INVESTIGATOR TRAINING IN EUROPE
Planning, preparing and organising clinical trials at the inves-
tigator site has become a highly complex task taking into con-
sideration the need to protect the patients, to generate reliable
data, to perform the trials efficiently, with increasingly short
timelines, and to fulfill all quality requirements according to
the current legislation and inspection requirements. Obviously,
it is important that European sites are able to perform clini-
cal trials according to the required standards. While the number
of performed clinical trials has only slightly decreased in the
last years, other regions like Eastern Europe, Asia and South
America have become more attractive to biopharmaceutical
industry sponsors, leading to a decreased number of studies
they initiate in Western- and Central Europe. Overall, the num-
ber of clinical trials in Europe has decreased by 20% in the
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last 3 years 1 2 3 4 5. The complexity of clinical trials and the
regulatory requirements have increased significantly in the last
few years, requiring an increasing level of scientific, method-
ological, regulatory and organisational know-how to be able to
perform clinical trials efficiently. Despite pharmaceutical indus-
try’s increase of the percentage of multi-national trials and the
number of sites involved, the number of enrolled patients per
year has not increased (EUdraCT database), making the plan-
ning and execution of clinical trials difficult and costly. In Europe,
clinical research (clinical trials science and methodology) is often
not highly regarded academically and collaboration with phar-
maceutical industry in performing the trials is still subject to
suspicion of commercial bias and perceived lack of academic
credibility, as presented in a European Science Foundation (ESF)
report on investigator-driven clinical trials 6. The most impor-
tant recommendation of this report to reverse this trend was:
To improve the education, training and career structure and
opportunities for scientists involved in patient-oriented clinical
research.
The principal clinical investigator has a crucial role in the
clinical trial performance at the site. Clinical investigators are
physicians who, in most cases, primarily perform diagnosis and
treatment of diseases of patients under their care. Medicines
under clinical investigation and the organisation of clinical trials
are only a small part of their daily hectic and usually overloaded
clinical activities. However, having the skills and infrastructure to
enrol more patients makes the performance of a trial more worth-
while in every aspect. Yet, there is still broad lack of understanding
amongst investigators about the benefits of training in efficient
and reliable clinical trial performance.
All parties involved in organising and supervising clinical
research agree that investigators need adequate training to carry
out their duties. In particular this is stated in the International
Conference onHarmonisation (ICH)Guideline for GoodClinical
Practice (GCP) and in the European Clinical Trials Directive
2001/20/EC. Large biopharmaceutical companies have developed
their own GCP courses as a minimal requirement and demand
that every investigator attends these courses as a prerequisite to
become an investigator in their clinical trials. The current qual-
ification standards for investigators are generally vague and vary
widely between European Union (EU) countries. Only in Sweden,
UK, Switzerland, Hungary, and Lithuania a GCP certificate is a
1European clinical trial rules under fire, Nature, March 2009,
doi:10.1038/news.2009.163
2Managing clinical research in the UK, Warwick Business School,
December 2009, http://www.qmul.ac.uk/docs/research/65670.pdf
3UK doctors demand research reform, Nature, May 2010,
doi:10.1038/news.2010.243
4Clinical research footprint and strategic plan to promote clinical
research in Belgium, pwc, June 2012, http://pharma.be/assets/files/3229/3229
129860438902421759.pdf
5Europe faces decline in clinical trials activity, Public Service Europe,
March 2013, http://www.publicserviceeurope.com/article/3240/
europe-faces-decline-in-clinical-trials-activity
6Forward Look-Investigator-driven clinical trials, European Science
Foundation, March 2009, http://www.esf.org/fileadmin/Publicdocuments/
Publications/IDCT.pdf
minimum regulatory requirement to participate in clinical trials.
In some EU countries, like Germany or Italy, ethics committees
expect to see a GCP certificate as a demonstration of investiga-
tor suitability. However, training over one or two days in GCP
does not enable physicians to thoroughly comprehend their role
in protecting trial participants and to generate quality data in an
efficient way in all types of studies. Moreovermost ethics commit-
tees in Europe are satisfied with a curriculum vitae documenting
clinical credentials in the respective therapeutic area.
Clinical research is only very marginally subject to
undergraduate medical training in Europe, and there is no
post-graduate education obligation for physicians performing
and taking responsibility for clinical trials in most EU countries.
Clinical trial units in hospitals, private training providers and
some universities (e.g., Basel, Copenhagen, Leuven. . .) across
Europe have started to offer comprehensive investigator training
to improve the competence of their investigators and the num-
ber of clinical trials successfully performed in their hospitals.
However, these are local, spontaneous and often reactive activi-
ties. There is a need to develop a strategy for investigator training
in Europe that
• is demonstrably able to enhance efficiency and reliability of
investigator activities
• can be applied in all EU countries, fulfilling regulatory and
ethics committee requirements
• fulfils pharmaceutical industry’s quality expectations
• follows a syllabus that covers the full spectrum of investigator
activities, not just the GCP basics
• is adapted to investigators’ respective roles and responsibilities
in a clinical trial
• can be integrated into the investigators’ work schedule
• is provided by demonstrably qualified training organisations
• ensures demonstration of achieved learning outcomes
• is financially affordable
• can be performed without undue investment of investigators’
time.
The here proposed strategy for investigator training will fur-
ther improve the credibility of clinical research and increase
patient throughput in clinical studies, a key objective of the
Innovative Medicines Initiative (IMI).
PharmaTrain AND ECRIN
PharmaTrain is one of the IMI Education and Training projects
and focusses on the development of a comprehensive training
infrastructure in the area of pharmaceutical development which
includes the areas of pharmaceutical medicine, regulatory affairs
and clinical trial performance. The project is based on the creation
of a network of Diploma and Master Courses in pharmaceutical
development and in regulatory affairs, located in many differ-
ent countries. The PharmaTrain consortium partners, consisting
of universities, not-for-profit organisations and pharmaceutical
companies, have developed and implemented an advanced stan-
dard for content and teaching methodology based on an agreed
syllabus and curriculum and including e-learning opportunities.
PharmaTrain has established a European quality management
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infrastructure to assess quality, content and performance of the
associated courses, an infrastructure to manage the examina-
tion process in all associated courses and an IT platform within
EMTRAIN’s “on-course” database to enable easy identification of
the most suitable training opportunities.
ECRIN, the FP7-funded European Clinical Research
Infrastructures Network, is a sustainable, not-for-profit infras-
tructure supporting multinational clinical research projects in
Europe. ECRIN provides information, consulting and services to
academic investigators and sponsors in the preparation and in
the conduct of multi-national clinical studies, for any category
of clinical research and in any disease area. This is particularly
relevant for investigator-initiated (academic, non-industry spon-
sored) or small and medium enterprise-sponsored clinical trials
and for clinical research on rare diseases where international
cooperation is a key success factor. ECRIN is based on the
connection of coordinating centers for national networks of
clinical research centers and clinical trials units, able to provide
support and services to multinational clinical research. Relevant
tools for clinical researchers involved in multinational clinical
trials are available on the ECRIN website.
Based on global and other regions’ activities to increase
investigator competence like e.g., the Organisation for
Economic Co-operation and Development (OECD), Academy of
Pharmaceutical Physicians and Investigators (APPI), or Alliance
for Clinical Research Excellence and Safety (ACRES) initiatives,
there is an increasing wish to harmonize investigator training
requirements in the EU. However, at the same time it will be
vital to build an infrastructure that gives investigators easy and
affordable access to training and examination.
PharmaTrain and ECRIN have joined forces to utilize their
European reach and impact on clinical research to promote and
establish such a European investigator training infrastructure
leading to a clinical investigator certificate (CLIC). They invited
other organizations involved in investigator training to join an
Advisory Group in order to work out a suitable strategy.
DIFFERENT LEVELS OF COMPETENCE
Not all professionals involved in clinical research need to acquire
the same level of competence in clinical trial performance. In fact,
some are only involved in the study site team. Others assume
responsibility as principal investigators. Still others may con-
sider clinical research as a major component of their professional
life and even initiate new studies on sponsor level. A some-
what different combination of knowledge and skills is required
for investigators performing Phase I trials in a dedicated unit. A
training approach adapted to the training needs in human phar-
macology studies might be initiated in near future by experts in
that field.
To date a concept of 3 levels of competence has emerged. It is
found in the Swissmedic (Swiss Agency for Therapeutic Products)
guidelines 7, which distinguish sub-investigator, investigator and
sponsor-investigator, as well as in the USA-based APPI Statement
7Requirements for the training of co-investigators, principal investigators
and sponsor-investigators involved in clinical trials on therapeutic products,
http://www.swissmedic.ch/bewilligungen/00089/01100/index.html?lang=en
of Clinical Investigator Competence8, which relates them to the
depth of commitment to clinical research.
It is therefore recommended that courses offer the option of
different levels of training related to distinct responsibilities in the
performance of clinical trials:
• Level 1: site staff.
• Level 2: (principal) investigator (responsibility for a clinical
trial at a site).
• Level 3: sponsor-investigator (overall responsibility for a clini-
cal trial).
These 3 levels represent increasing competence and individuals
may move from one level to an upper level over time.
Level 1 encompasses a basic core of knowledge that is com-
mon to the various professionals in a study team involved in
the preparation and conduct of studies at investigational sites.
The target audience is therefore constituted by medical (sub-
investigator) and non-medical (study nurse, study coordinator,
study manager. . .) staff.
Level 2 represents the knowledge in regulatory and man-
agerial aspects of a clinical trial requested from a principal
investigator according to ICH-GCP definition, EU and national
legislation.
Level 3 corresponds to investigators for whom clinical
research is a major element of their professional life and who
assume responsibility for investigator-initiated trials. The term
“sponsor-investigator” is not optimal since in general the spon-
sor is an institution (e.g., an hospital or university) and not
an individual, but in contrast to “trial-initiating investigator,”
“sponsor-investigator” expresses the type of knowledge such type
of investigator needs to have.
These 3 levels also differ by their national vs. international
dimension. The content of the courses will include national reg-
ulations at level 1, an overview of the international regulatory
environment at level 2 and a detailed knowledge of EU and
international regulations at level 3.
To demonstrate the acquired level of knowledge required to
receive the respective Investigator Training Certificate, it is rec-
ommended to require a mandatory examination.
CONTENT AND LEARNING OUTCOMES OF CLINICAL
INVESTIGATOR COURSES
This question has been addressed in several documents:
• A European syllabus for Training Clinical Investigators9.
• Swissmedic guidelines defining the training content requested
for a sub-investigator, investigator and sponsor-investigator
respectively7.
• The APPI Consensus Statement8.
8Statement of clinical investigator competence, APPI Consensus Statement,
Monitor, August 2011: 79–82
9A European Syllabus for Training Clinical Investigators,
European Science Foundation, July 2003, http://www.esf.org/
publications/medical-sciences.html?txccdamdlpi1%5Bpointer%5D=1&
cHash=5facba551e13516e3a4b9154f8680f35
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• The IMI PharmaTrain Manual10 defining the contents
and learning outcomes of courses in pharmaceutical
medicine/medicines development sciences, of which clinical
research is an essential component.
Based on these previous documents, a syllabus and learning
outcomes have been defined for each of the 3 levels defined above
(Tables 1–3). The course content is presented incrementally, i.e.,
the level 3 syllabus and learning outcomes only contain the ele-
ments to be taught in addition to those of levels 1 and 2. This
syllabus is currently focused on medicinal products and should
later be expanded to other areas of research such as medical
devices.
FORMAT AND DURATION OF THE COURSES FOR CLINICAL
INVESTIGATORS
It will be left to the student to decide on the number of hours
he/she will invest into learning and the modus of learning.
Courses for clinical investigators can be entirely face-to-face
or involve mostly e-learning complemented by a short face-
to-face session. The PharmaTrain e-library includes a course
for clinical investigators in which the content has been strat-
ified according to the 3 levels of competence, mentioned
earlier11. There is a broad offering of investigator training
options by many different organisations in different coun-
tries. These existing resources should be used, provided they
are in line with the above mentioned syllabus and learning
outcomes.
At level 1 and 2, the courses could be given in the local language
or in English, whereas English is mandatory for level 3.
The optimal duration of a clinical investigator course will
depend on the targeted level of competence. The ESF syllabus sug-
gested a 3–5 days training duration9. Although these figures are
approximate (especially for e-learning) and not mandatory, the
following durations are recommended:
• 2 days (16 h) for level 1.
• 5 days (40 h) for level 2, that is a 3 days increment as compared
to level 1.
• 8 days (64 h) for level 3, that is a 3 days increment as compared
to level 2.
Beside these basic courses, there is also room for more exten-
sive courses such as full master programmes in clinical research,
or diploma courses in clinical trial practices andmanagement that
are organised in some European countries.
A grandfathering clause is proposed for a duration of 3 years
after implementation, allowing that the established investiga-
tors will be eligible to receive the certificate without passing the
examination, provided that they sit the examination in form of
self-control and submit a detailed CV, including the list of clinical
trials in which they have been involved.
10PharmaTrain Manual Curriculum Standards and Best Practices, June 2013,
http://www.pharmatrain.eu
11eCLIC, http://www.pharmatrain.eu/ or http://clic.bio-med.ch/cms/
Default.aspx
A Continuous Professional Development (CPD) programme
requiring the attendance to short refresher/update courses, at least
every 3 years, should also be established.
COURSE ACCREDITATION
As part of PharmaTrain’s network of course providers in pharma-
ceutical medicine/medicines development sciences, a European
network of CLIC course providers will be established. The course
providers will be accredited by the PharmaTrain Central Office
according to the agreed and implemented PharmaTrain quality
standards.
PharmaTrain will establish a “CLIC Course Recognition”
award for those courses fulfilling the PharmaTrain quality criteria
and syllabus/learning outcome requirements.
It is proposed to develop a database in the PharmaTrain
Central Office containing the accredited courses as well as the
contact details of those certified course participants who gave per-
mission to keep their personal data in order to remind them of
their CPD needs.
EXAMINATION AND CERTIFICATION
It is proposed that one obligatory face-to-face day encompassing
the examination will be required as pre-requisite for the certifi-
cate. Examinations will be organized at a local level by course
providers. Candidates who have not attended courses will be
allowed to sit these examinations. These will consist of a multiple
choice questionnaire (MCQ) involving the physical presence of
candidates in order to be sure of their identity; this could change
with time in relation with technological evolution. Distinct ques-
tions will be proposed for the different levels of competence
required. TheMCQs should include at least 50 questions (level 1),
60 questions (level 2), or 80 questions (level 3).
It is proposed to establish a pool of ca. 500 questions for the
3 levels, subject to a continuous improvement process and sen-
sitivity analyses. The questions will be made publicly available
(“drivers-licence approach”).
The course/examination providers will request 80% of the
questions from the PharmaTrain Central Office, whereas 20% of
the questions can be related to national legislation/regulations
and be prepared by the local examination/course providers.
At levels 1 and 2, the examination might be in national lan-
guage rather than English; national course providers will be
encouraged to provide the translation of the questions to the
central question pool.
Management and scoring of the examinations will be per-
formed by a central unit, according to the Good Examination
Guidelines established by PharmaTrain. Answers will be entered
on a computerised sheet and automatically evaluated by the
central unit selected by the PharmaTrain Central Office, to
ensure objectivity and to maintain standards and comparability
of scoring.
Certificates will be issued preferably by national universities. If
this is not achievable in a country then issuing by national physi-
cian associations or nation-wide academic institutions should be
sought.
The certificates will be delivered by the course provider con-
taining the university stamp, the PharmaTrain and ECRIN labels
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and the course provider’s label. The certificates will mention the
level of competence and all nationally required information.
CONDITIONS OF SUCCESS AND IMPACT
The development of a European programme of clinical investiga-
tor training and certification aims at further increasing the quality
of clinical trials in Europe, in order to support the faster discovery
and development of better medicines for patients and to enhance
Europe’s competitiveness, which are the goals of the IMI. At the
end of the day the impact of investigator training on the qual-
ity of clinical research will need to be evaluated using qualitative
and quantitative indicators, such as a decrease in the number of
observations during audits and inspections.
Success depends on the full cooperation and involvement
of investigators, sponsors, ethics committees, medical associa-
tions and regulatory authorities. In particular the pharmaceuti-
cal sponsors should view clinical investigator training as a new
opportunity to enhance quality and efficiency, with the ultimate
aim of accruing more patients data in European countries and
facilitating EU regulatory filings. These training courses should
reduce/obviate the need for sponsor-organised GCP training ses-
sions that cover only part of the training needs and lead to a
needless redundancy. Sponsors should recommend and motivate
their investigators to attend formal training courses to obtain for-
mal certification. Ethics committees and regulatory authorities
should aim at harmonizing regulations and creating a minimal
and mutually recognised certification requirement for investiga-
tors throughout Europe.
RECOMMENDATIONS
The following steps are recommended to improve and harmonize
clinical investigator training and certification in Europe.
• EU and national regulatory authorities should harmonize
regulations and create a minimal and mutually recognized
certification requirement for investigators throughout the EU.
• Pharmaceutical sponsors should reduce the need for redundant
GCP training sessions that cover only part of the needs and
motivate instead investigators to attend training courses and
obtain formal certification.
• A European platform should be created to provide a suitable
course and examination infrastructure, assess courses and har-
monise examinations throughout the EU in order to improve
quality and comparability. That platform should be based on
current and past European projects in the field such as IMI
PharmaTrain and ECRIN.
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